Basaglar (insulin glargine) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to: improve blood sugar levels in adults ...

Mylan and Biocon's Semglee (insulin glargine injection) is now the second approved "follow-on" biologic of Sanofi's Lantus. Adults with Type 2 diabetes, and adult and pediatric patients with Type 1 ...

Sanofi has put off a biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the French drugmaker and U.S.-based Eli Lilly & Co. agreed to a royalty deal covering ...

TRENTON, N.J. (AP) - A less-expensive version of the world’s top-selling insulin, Sanofi’s Lantus, could go on sale in the U.S. late next year. The French drugmaker said Monday it settled a lawsuit ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

Amid consumer angst and political pressure over the cost of life-saving insulin, Sanofi announced Thursday it would slash the price of its most-prescribed insulin, Lantus. Sanofi said it will cut the ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

PETERSBURG — Civica Inc. has announced plans to use its Petersburg facility to manufacture and distribute insulins to its hospital partners across the United States. Once approved, these new insulins ...

When the US Food and Drug Administration (FDA) approved Semglee, the first interchangeable biosimilar insulin, the agency pitched it as having the potential to be less costly than insulins currently ...

Lantus ® (“Lantus”) is Sanofi’s insulin glargine product. The U.S. Food and Drug Administration (FDA) first approved Lantus in 2000 as a sterile solution of insulin glargine for use as an injection.

The FINANCIAL — Sanofi announced on September 28 that it has reached a settlement agreement with Eli Lilly and Company, which addresses patents on Sanofi’s Lantus SoloSTAR (insulin glargine). The ...